Compass Therapeutics (CMPX) Stock Forecast & Price Target

Compare

436 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CMPX Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Compass

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CMPX Stock 12 Month Forecast

Average Price Target

$12.67

▲(145.07% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Compass Therapeutics in the last 3 months. The average price target is $12.67 with a high forecast of $24.00 and a low forecast of $8.00. The average price target represents a 145.07% change from the last price of $5.17.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","25":"$25","6.25":"$6.25","12.5":"$12.5","18.75":"$18.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,6.25,12.5,18.75,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.37,6.803076923076923,8.236153846153845,9.669230769230769,11.102307692307692,12.535384615384615,13.968461538461536,15.401538461538461,16.834615384615383,18.267692307692307,19.70076923076923,21.133846153846154,22.566923076923075,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.37,5.931538461538461,6.493076923076924,7.054615384615385,7.616153846153846,8.177692307692308,8.739230769230769,9.30076923076923,9.862307692307692,10.423846153846153,10.985384615384614,11.546923076923077,12.108461538461539,{"y":12.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.37,5.572307692307692,5.774615384615385,5.976923076923077,6.179230769230769,6.381538461538462,6.583846153846154,6.786153846153846,6.9884615384615385,7.190769230769231,7.393076923076923,7.595384615384615,7.797692307692308,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.66,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.74,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.46,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.37,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$24.00

Average Price Target$12.67

Lowest Price Target$8.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

John Newman

Canaccord Genuity

$10

Buy

93.42%

Upside

Reiterated

01/08/26

Compass Therapeutics (CMPX) Gets a Buy from Canaccord GenuityWe maintain our Buy rating on CMPX based on our confidence in the upcoming Phase2/3 data for tovecimig.

Charles Zhu

LifeSci Capital

$10→$12

Buy

132.11%

Upside

Reiterated

01/06/26

High-Conviction Buy on Compass Therapeutics: Near-Term Tovecimig Registration Data and Differentiated PD-1 x PD-L1 Bispecific Drive Favorable Risk-Reward

Joseph Pantginis

H.C. Wainwright

$24

Buy

364.22%

Upside

Reiterated

01/06/26

Compass Therapeutics: Strong Cash Position and 2026 Clinical Catalysts Underpin Reiterated Buy Rating

Matt Phipps

William Blair

Buy

―

Initiated

01/05/26

Compass Therapeutics: Emerging Bispecific Portfolio Positions Tovecimig to Redefine Second-Line Biliary Tract Cancer Standard of Care

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$4.96→$8

Buy

54.74%

Upside

Reiterated

12/18/25

Wedbush Remains a Buy on Compass Therapeutics (CMPX)

Li Watsek

Cantor Fitzgerald

Buy

―

Initiated

12/03/25

Compass Therapeutics initiated with an Overweight at Cantor FitzgeraldCompass Therapeutics initiated with an Overweight at Cantor Fitzgerald

Reni Benjamin

Citizens JMP

$10

Buy

93.42%

Upside

Initiated

12/03/25

Compass Therapeutics initiated with an Outperform at Citizens JMPCompass Therapeutics initiated with an Outperform at Citizens JMP

Biren Amin

Piper Sandler

$12

Buy

132.11%

Upside

Reiterated

11/10/25

Compass Therapeutics (CMPX) Receives a Buy from Piper Sandler

Stephen Willey

Stifel Nicolaus

$11→$12

Buy

132.11%

Upside

Reiterated

08/15/25

Stifel Nicolaus Sticks to Their Buy Rating for Compass Therapeutics (CMPX)

Andrew Berens

Leerink Partners

$6→$7

Buy

35.40%

Upside

Reiterated

08/12/25

Leerink Partners Reaffirms Their Buy Rating on Compass Therapeutics (CMPX)

Michael Schmidt

Guggenheim

$10→$12

Buy

132.11%

Upside

Reiterated

08/11/25

Compass Therapeutics price target raised to $12 from $10 at GuggenheimCompass Therapeutics price target raised to $12 from $10 at Guggenheim

Sean McCutcheon

Raymond James

Buy

74.08%

Upside

Reiterated

08/11/25

Raymond James Sticks to Its Buy Rating for Compass Therapeutics (CMPX)

Maury Raycroft

Jefferies

Buy

54.74%

Upside

Reiterated

02/10/25

Optimistic Buy Rating for Compass Therapeutics Due to Promising CTX-009 Trial Results and Market Potential

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

John Newman

Canaccord Genuity

$10

Buy

93.42%

Upside

Reiterated

01/08/26

Compass Therapeutics (CMPX) Gets a Buy from Canaccord GenuityWe maintain our Buy rating on CMPX based on our confidence in the upcoming Phase2/3 data for tovecimig.

Charles Zhu

LifeSci Capital

$10→$12

Buy

132.11%

Upside

Reiterated

01/06/26

High-Conviction Buy on Compass Therapeutics: Near-Term Tovecimig Registration Data and Differentiated PD-1 x PD-L1 Bispecific Drive Favorable Risk-Reward

Joseph Pantginis

H.C. Wainwright

$24

Buy

364.22%

Upside

Reiterated

01/06/26

Compass Therapeutics: Strong Cash Position and 2026 Clinical Catalysts Underpin Reiterated Buy Rating

Matt Phipps

William Blair

Buy

―

Initiated

01/05/26

Compass Therapeutics: Emerging Bispecific Portfolio Positions Tovecimig to Redefine Second-Line Biliary Tract Cancer Standard of Care

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$4.96→$8

Buy

54.74%

Upside

Reiterated

12/18/25

Wedbush Remains a Buy on Compass Therapeutics (CMPX)

Li Watsek

Cantor Fitzgerald

Buy

―

Initiated

12/03/25

Compass Therapeutics initiated with an Overweight at Cantor FitzgeraldCompass Therapeutics initiated with an Overweight at Cantor Fitzgerald

Reni Benjamin

Citizens JMP

$10

Buy

93.42%

Upside

Initiated

12/03/25

Compass Therapeutics initiated with an Outperform at Citizens JMPCompass Therapeutics initiated with an Outperform at Citizens JMP

Biren Amin

Piper Sandler

$12

Buy

132.11%

Upside

Reiterated

11/10/25

Compass Therapeutics (CMPX) Receives a Buy from Piper Sandler

Stephen Willey

Stifel Nicolaus

$11→$12

Buy

132.11%

Upside

Reiterated

08/15/25

Stifel Nicolaus Sticks to Their Buy Rating for Compass Therapeutics (CMPX)

Andrew Berens

Leerink Partners

$6→$7

Buy

35.40%

Upside

Reiterated

08/12/25

Leerink Partners Reaffirms Their Buy Rating on Compass Therapeutics (CMPX)

Michael Schmidt

Guggenheim

$10→$12

Buy

132.11%

Upside

Reiterated

08/11/25

Compass Therapeutics price target raised to $12 from $10 at GuggenheimCompass Therapeutics price target raised to $12 from $10 at Guggenheim

Sean McCutcheon

Raymond James

Buy

74.08%

Upside

Reiterated

08/11/25

Raymond James Sticks to Its Buy Rating for Compass Therapeutics (CMPX)

Maury Raycroft

Jefferies

Buy

54.74%

Upside

Reiterated

02/10/25

Optimistic Buy Rating for Compass Therapeutics Due to Promising CTX-009 Trial Results and Market Potential

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Compass Therapeutics

1 Month

xxx

Success Rate

4/5 ratings generated profit

Average Return

+16.16%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +16.16% per trade.

3 Months

xxx

Success Rate

9/11 ratings generated profit

Average Return

+37.35%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 81.82% of your transactions generating a profit, with an average return of +37.35% per trade.

1 Year

Michael SchmidtGuggenheim

Success Rate

5/5 ratings generated profit

Average Return

+126.62%

reiterated a buy rating 5 months ago

Copying Michael Schmidt's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +126.62% per trade.

2 Years

xxx

Success Rate

11/11 ratings generated profit

Average Return

+173.75%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +173.75% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CMPX Analyst Recommendation Trends

Rating

Aug 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CMPX has received 13 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. CMPX average Analyst price target in the past 3 months is 12.67.

Each month's total comprises the sum of three months' worth of ratings.

CMPX Financial Forecast

CMPX Earnings Forecast

Next quarter’s earnings estimate for CMPX is -$0.10 with a range of -$0.14 to -$0.02. The previous quarter’s EPS was -$0.08. CMPX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year CMPX has Performed in-line its overall industry.

CMPX Sales Forecast

Next quarter’s sales forecast for CMPX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CMPX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year CMPX has Performed in-line its overall industry.

CMPX Stock Forecast FAQ

What is CMPX’s average 12-month price target, according to analysts?

Based on analyst ratings, Compass Therapeutics’s 12-month average price target is 12.67.

What is CMPX’s upside potential, based on the analysts’ average price target?

Compass Therapeutics has 145.07% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CMPX a Buy, Sell or Hold?

Compass Therapeutics has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Compass Therapeutics’s price target?

The average price target for Compass Therapeutics is 12.67. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $24.00 ,the lowest forecast is $8.00. The average price target represents 145.07% Increase from the current price of $5.17.

What do analysts say about Compass Therapeutics?

Compass Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of CMPX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Compass Therapeutics (CMPX) Stock Forecast & Price Target

CMPX Analyst Ratings

CMPX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Compass Therapeutics

CMPX Analyst Recommendation Trends

CMPX Financial Forecast

CMPX Earnings Forecast

CMPX Sales Forecast

CMPX Stock Forecast FAQ

Detailed List of Analyst Forecasts